Metoprolol Tartrate Ipca Laboratories Uk

Metoprolol Tartrate, the active ingredient in Metoprolol Tartrate Ipca Laboratories Uk, is a beta blocker presented as a tablet for oral use. It treats hypertension, angina pectoris, post‑myocardial infarction, heart failure and certain cardiac arrhythmias in adult patients.

GNH USA supplies Metoprolol Tartrate Ipca Laboratories Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Tartrate is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

- Hypertension: lowers blood pressure by reducing heart rate and cardiac output. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Post‑myocardial infarction: reduces risk of recurrent infarction and improves survival. - Heart failure: improves ventricular function and reduces symptoms. - Cardiac arrhythmias: controls heart rate in atrial fibrillation and other supraventricular tachyarrhythmias.

Metoprolol Tartrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Cold extremities - Bradycardia (slow heart rate) - Gastrointestinal upset (nausea, abdominal discomfort) - Headache

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma - Allergic reactions (rash, angioedema) - Depression or mood changes - Cardiogenic shock

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Cardiovascular assessment: avoid in patients with severe bradycardia or advanced heart block. - Respiratory conditions: use cautiously in asthma or chronic obstructive pulmonary disease. - Diabetes monitoring: may mask hypoglycaemia symptoms; adjust glucose monitoring. - Concomitant beta‑blockers: avoid additive negative chronotropic effects. - Pregnancy considerations: safety category unknown; prescribe only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Metoprolol Tartrate can interact with several drug classes; some combinations should be avoided, while others require close monitoring.

Major Interactions (Avoid): - Calcium channel blockers (verapamil, diltiazem): may cause profound bradycardia. - CYP2D6 inhibitors (quinidine, propafenone): increase metoprolol plasma levels. - Clonidine: abrupt discontinuation after concurrent use can precipitate hypertension. - Insulin or oral hypoglycemics: enhanced glucose‑lowering effect. - Non‑selective beta blockers: additive negative cardiac effects.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive efficacy. - Diuretics: risk of excessive blood pressure reduction. - Antidepressants (SSRIs, SNRIs): potential for bradycardia. - Antithyroid drugs: may alter heart rate response. - Anesthetic agents: increased risk of intra‑operative hypotension.